Technetium (99mTc) arcitumomab
Intravenous | |
|---|---|
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Elimination half-life | 13 ± 4 hours |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Molar mass | 54 kDa[citation needed] |
| (verify) | |
Technetium (99mTc) arcitumomab is a drug used for the diagnostic imaging of
Fab' fragment of a monoclonal antibody (arcitumomab, trade name CEA-Scan) and a radionuclide, technetium-99m
.
Chemistry
Technetium (99mTc) arcitumomab is an
reduction
.
Before application, arcitumomab is reconstituted with a solution of the radioactive agent sodium
technetium generator.[1]
Mechanism of action
Arcitumomab recognizes
Contraindications
Technetium (99mTc) arcitumomab is
contraindicated for patients with known allergies or hypersensitivity to mouse proteins, as well as during pregnancy. Women should pause breast feeding for 24 hours after application of the drug.[1]
Adverse effects and overdose
Only mild and transient side effects have been observed, mostly immunological reactions like
grand mal after application.[1]
Radioactivity can lead to
such an overdose is unlikely.References
- ^ a b c d e f "CEA-Scan Summary of Product Characteristics". Immunomedics. Archived from the original on 2016-03-13. Retrieved 2009-10-28.
- PMID 11289125.
- PMID 7493346.
Further reading
- Primus FJ, Newell KD, Blue A, Goldenberg DM (February 1983). "Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies". Cancer Research. 43 (2): 686–92. PMID 6184152.
- Hansen HJ, Jones AL, Sharkey RM, Grebenau R, Blazejewski N, Kunz A, et al. (February 1990). "Preclinical evaluation of an "instant" 99mTc-labeling kit for antibody imaging". Cancer Research. 50 (3 Suppl): 794s–798s. PMID 2297726.
- Hughes K (1995). "Use of radioimmunodetection with CEAScan in planning for resection of recurrent colorectal cancer". Proc Amer Soc Clin Oncol. 14: 544.
- Moffat FL, Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley FS, Goldenberg DM (August 1996). "Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group". Journal of Clinical Oncology. 14 (8): 2295–305. PMID 8708720.